Coherus Oncology (CHRS) Income from Continuing Operations (2013 - 2026)
Coherus Oncology (CHRS) reported Income from Continuing Operations of 36935000.0 for Q1 2026, up 22.07% on a YoY basis from 30256046.91 in Q1 2025, and up 20.31% sequentially from 46347000.0 in Q4 2025.
Coherus Oncology (CHRS) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 14 years of Income from Continuing Operations data on file, last reported at 36935000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 22.07% year-over-year to 36935000.0; the trailing twelve-month figure through Mar 2026 stood at 172661000.0 (up 11.88% YoY), and the FY2025 full-year result was 183124000.0, up 15.03% from the prior year.
- Income from Continuing Operations advanced to 36935000.0 in Q1 2026, from 46347000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 36935000.0 in Q1 2026 to a low of 96084000.0 in Q1 2022.
- A 5-year average of 56840235.29 and a median of 47599000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 124.9% in 2022 and soared 54.25% in 2023, its largest moves.
- Tracing CHRS's Income from Continuing Operations over 5 years: stood at 58870000.0 in 2022, then sank by 35.3% to 79653000.0 in 2023, then surged by 42.13% to 46093000.0 in 2024, then slipped by 0.55% to 46347000.0 in 2025, then increased by 20.31% to 36935000.0 in 2026.
- Business Quant data shows CHRS's Income from Continuing Operations at 36935000.0 in Q1 2026, 46347000.0 in Q4 2025, and 44517000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn | -36.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.94 Mn |
| Dec 31, 2025 | -46.35 Mn |
| Sep 30, 2025 | -44.52 Mn |
| Jun 30, 2025 | -44.86 Mn |
| Mar 31, 2025 | -47.40 Mn |
| Dec 31, 2024 | -46.09 Mn |
| Sep 30, 2024 | -47.60 Mn |
| Jun 30, 2024 | -54.85 Mn |
| Mar 31, 2024 | -68.04 Mn |
| Dec 31, 2023 | -79.65 Mn |
| Sep 30, 2023 | -39.64 Mn |
| Jun 30, 2023 | -42.87 Mn |
| Mar 31, 2023 | -75.73 Mn |
| Dec 31, 2022 | -58.87 Mn |
| Sep 30, 2022 | -86.65 Mn |
| Jun 30, 2022 | -50.15 Mn |
| Mar 31, 2022 | -96.08 Mn |
| Dec 31, 2021 | -45.68 Mn |
| Sep 30, 2021 | -38.53 Mn |
| Jun 30, 2021 | -29.90 Mn |